Singapore markets closed

The Zacks Analyst Blog Highlights: Tesla, Zoetis, Target, Boston Scientific and Moody's

Zacks Equity Research

For Immediate Release

Chicago, IL – April 9, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Tesla TSLA, Zoetis ZTS, Target TGT, Boston Scientific BSX and Moody's MCO.

Here are highlights from Wednesday’s Analyst Blog:

Top Research Reports for Tesla, Zoetis and Target

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Tesla, Zoetis and Target. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Tesla’s shares have outperformed the Zacks Domestic Automotive industry over the past six months (+123.1% vs. +9.6%). The Zacks analyst believes that rising Model 3 delivery, which forms bulk of the automaker’s overall deliveries, is aiding the company’s top-line growth.

With Model 3 sedan being its flagship vehicle, Tesla has established itself as a leader in the EV segment. Tesla’s upcoming product launches, including Model Y and Semi Truck, are expected to further boost prospects.

However, with China being an important market for Tesla, economic slowdown in the country is weighing on the firm. Tesla’s massive debt and high capex also play spoilsports. Waning demand for Model S/X is another concern. Thus, investors are advised to wait for a better entry point.

Shares of Zoetis have gained 24.3% over the past year against the Zacks Drugs industry’s fall of -23.6%. The Zacks analyst believes that key dermatology products, such as Apoquel and Cytopoint, continue to penetrate the market and generate additional revenues.

Zoetis maintains momentum on the back of growth in new parasiticide products, vaccines and a solid dermatology portfolio. Increased sales of parasiticides, including ProHeart 12 and Simparica, further boosted performance. The Abaxis acquisition has further strengthened its leading portfolio. Zoetis has been making other prudent acquisitions.

However, the cattle market is witnessing challenges for beef and dairy customers. Moreover, the swine market is being affected by the African swine fever in China. Competition is stiff as well.

Target’s shares have lost -20.5% over the past three months against the Zacks Retail- Discount & Variety industry’s fall of -12.3%. The Zacks analyst notes that Apparel & Accessories’ performance remained soft. Management remains wary of persistent decline in higher-margin discretionary items sales due to the coronavirus outbreak.

The stock came under pressure in spite of the company witnessing higher traffic and sales for Essentials and Food & Beverage categories in the month of March. Owing to the pandemic, Target has not only withdrawn its first-quarter and fiscal 2020 view but also shifted certain strategic projects.

Nonetheless, the company remains focused on enhancing omni-channel capabilities, expanding same-day delivery options and rationalizing supply chain. However, management sees additional $300 million cost rise for the first quarter putting pressure on margins.

Other noteworthy reports we are featuring today include Boston Scientific and Moody's.

Free: Zacks’ Single Best Stock Set to Double

Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.

See 5 Stocks Set to Double>>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                                   

https://www.zacks.com                                                 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Click to get this free report Moody's Corporation (MCO) : Free Stock Analysis Report Target Corporation (TGT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Zoetis Inc. (ZTS) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research